US equities
|
MU
$1,029.00
▼-0.66%
NVDA
$229.28
▼-0.52%
SPCX
$162.57
▲+1.25%
TSLA
$382.70
▲+2.05%
AAPL
$336.64
▼-1.11%
MSFT
$535.07
▲+2.38%
AMZN
$262.43
▲+3.29%
META
$718.67
▼-0.31%
MU
$1,029.00
▼-0.66%
NVDA
$229.28
▼-0.52%
SPCX
$162.57
▲+1.25%
TSLA
$382.70
▲+2.05%
AAPL
$336.64
▼-1.11%
MSFT
$535.07
▲+2.38%
AMZN
$262.43
▲+3.29%
META
$718.67
▼-0.31%
FinancialContent
Sign in
Markets
Overview
News
World markets
Treasuries
Currencies
Commodities
Economy
Stocks
Overview
Most active
Gainers
Losers
Largest companies
52-week gainers
52-week losers
ETFs
Overview
Popular funds
Most active
Gainers
Losers
News
Research
Search
Sectors
Myriad Genetics, Inc. - Common Stock
(NQ:
MYGN
)
4.310
+0.110 (+2.62%)
Delayed Quote
Updated: 4:00 PM EDT, Oct 9, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Myriad Genetics, Inc. - Common Stock
< Previous
1
2
3
4
5
6
7
Next >
Myriad Genetics and SOPHiA GENETICS Announce New Collaboration to Advance Prostate Genomic Instability Score Technology
October 08, 2026
From
Myriad Genetics, Inc.
Via
GlobeNewswire
Myriad Genetics Appoints Vishal Sikri Executive Vice President - Commercial
September 16, 2026
From
Myriad Genetics, Inc.
Via
GlobeNewswire
Myriad Genetics to Present at 2026 Wells Fargo Healthcare Conference
August 27, 2026
From
Myriad Genetics, Inc.
Via
GlobeNewswire
MYGN SHAREHOLDER ALERT: Myriad Genetics Inc. Investors Encouraged to Contact Kirby McInerney LLP About Potential Securities Laws Violations
August 13, 2026
From
Kirby McInerney LLP
Via
Business Wire
MYGN Investors Have Opportunity to Join Myriad Genetics, Inc. Fraud Investigation with SBS Law
August 08, 2026
From
Schall, Brown & Schwartz LLP
Via
Business Wire
MYRIAD INVESTIGATION ALERT: Bragar Eagel & Squire, P.C. is Investigating Myriad Genetics, Inc. on Behalf of Myriad Stockholders and Encourages Investors to Contact the Firm
August 07, 2026
From
Bragar Eagel & Squire
Via
GlobeNewswire
MYGN Investor Alert: Levi & Korsinsky Notifies Investors of Investigation Into Myriad Genetics (MYGN)
August 05, 2026
From
Levi & Korsinsky, LLP
Via
Business Wire
Myriad Genetics Reports Second Quarter 2026 Financial Results; Deploying New Initiatives Focused on Driving Increased Efficiency, Productivity and Scalability
July 30, 2026
From
Myriad Genetics, Inc.
Via
GlobeNewswire
Myriad Genetics to Release Second Quarter 2026 Financial Results on July 30, 2026
July 23, 2026
From
Myriad Genetics, Inc.
Via
GlobeNewswire
Myriad Genetics Launches FirstGene® Multiple Prenatal Screen
July 21, 2026
The only lab test to run four prenatal genetic screens simultaneously as early as eight weeks gestation
From
Myriad Genetics, Inc.
Via
GlobeNewswire
New Large-Scale Meta-Analysis Demonstrates Strong Prognostic Performance of Myriad’s Prolaris® Biopsy Test in Localized Prostate Cancer
July 02, 2026
Findings from 14 studies involving more than 8,000 patients show Prolaris adds insight beyond conventional clinical risk categories
From
Myriad Genetics, Inc.
Via
GlobeNewswire
Myriad Genetics Expands Availability of Precise MRD™ for Colorectal, Renal and Breast Cancers, Supported by New Publication
June 23, 2026
Publication of MONITOR-Breast study marks latest milestone for clinical validity of Precise MRD
From
Myriad Genetics, Inc.
Via
GlobeNewswire
Myriad Genetics Names Raj Jampa as New Chief Technology Officer
June 02, 2026
From
Myriad Genetics, Inc.
Via
GlobeNewswire
Myriad Genetics Highlights Data Showing Broad Clinical Utility of Precise MRD Assay at 2026 ASCO Annual Meeting
May 27, 2026
Six ASCO abstracts and an industry expert theater session underscore Myriad’s leadership in the cancer care continuum
From
Myriad Genetics, Inc.
Via
GlobeNewswire
Myriad Genetics Launches Prolaris® + AI, the First Prostate Cancer Test to Combine Genomics and Digital Pathology Artificial Intelligence (AI)
May 26, 2026
New PATHOMIQ AI integration helps clinicians tailor active surveillance with greater confidence
From
Myriad Genetics, Inc.
Via
GlobeNewswire
Actress Jackie Tohn Got Results Nobody Wants But They May Have Saved Her Life
May 15, 2026
The Netflix star partners with Myriad Genetics to tell her BRCA1 story and why she wants everyone to know about hereditary cancer testing
From
Myriad Genetics, Inc.
Via
GlobeNewswire
Myriad Genetics to Participate in Upcoming Investor Healthcare Conferences
May 07, 2026
From
Myriad Genetics, Inc.
Via
GlobeNewswire
Myriad Genetics Reports First Quarter 2026 Financial Results; Reiterates 2026 Financial Guidance Reflecting Ongoing Progress in the Cancer Care Continuum Business
May 05, 2026
From
Myriad Genetics, Inc.
Via
GlobeNewswire
Myriad Genetics National Survey: 88% of Patients with Depression and/or Anxiety Would Feel More Confident with a Personalized Mental Health Care Plan
April 30, 2026
From
Myriad Genetics, Inc.
Via
GlobeNewswire
Myriad Genetics to Release First Quarter 2026 Financial Results on May 5, 2026
April 28, 2026
From
Myriad Genetics, Inc.
Via
GlobeNewswire
Myriad Genetics to Deliver Six Abstracts, Including Two Podiums, at AACR 2026
April 16, 2026
From
Myriad Genetics, Inc.
Via
GlobeNewswire
Myriad Genetics Expands Access for MyChoice Test to Prostate Cancer Patients in Japan
April 14, 2026
From
Myriad Genetics, Inc.
Via
GlobeNewswire
Myriad Genetics Underscores Commitment to Cancer Care Continuum with New Data Presentations at SGO Annual Meeting
April 09, 2026
From
Myriad Genetics, Inc.
Via
GlobeNewswire
Myriad Genetics Receives FDA Approval of the MyChoice CDx Test as the Companion Diagnostic for Zejula (niraparib) for Patients with Ovarian Cancer
March 17, 2026
Approval reinforces Myriad’s leadership in comprehensive HRD testing and establishes MyChoice CDx as the only FDA-approved companion diagnostic for Zejula in the United States
From
Myriad Genetics, Inc.
Via
GlobeNewswire
Myriad Commercially Launches Precise MRD with Select Community Oncologists
March 02, 2026
Launch Represents Significant Step to Broader Commercialization
From
Myriad Genetics, Inc.
Via
GlobeNewswire
Six presented abstracts at ASCO-GU 2026 reinforce the clinical impact of Myriad’s Precise MRD, Prolaris, and MyRisk tests
February 24, 2026
From
Myriad Genetics, Inc.
Via
GlobeNewswire
Myriad Genetics Reports Fourth Quarter and Full-Year 2025 Financial Results; Reiterates 2026 Financial Guidance Reflecting Strengthened Execution
February 23, 2026
From
Myriad Genetics, Inc.
Via
GlobeNewswire
FirstGene Study Demonstrates High Analytical Sensitivity and Specificity for Each Component of the Test
February 19, 2026
Analytical validation of FirstGene Multiple Prenatal Screen published in Clinical Chemistry
From
Myriad Genetics, Inc.
Via
GlobeNewswire
Myriad Genetics to Release Fourth Quarter and Full Year 2025 Financial Results on February 23, 2026
February 16, 2026
Management will participate in three upcoming investor healthcare conferences
From
Myriad Genetics, Inc.
Via
GlobeNewswire
Myriad Advances MRD Commercialization Timeline, Bolstered by New Study Data
January 27, 2026
Precise MRD™ to transition from research-use-only into a limited clinical launch in March 2026
From
Myriad Genetics, Inc.
Via
GlobeNewswire
< Previous
1
2
3
4
5
6
7
Next >
